Vosaroxin
As of the edition of 20 October 2026, Vosaroxin is a small molecule: stopped in 2017; acts on TOP2A and TOP2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Small molecule
- Registered trials
- 15, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Lungs and airways; Hormones; Immune system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 8 | 8 | 0 | 0 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 15 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sunesis Pharmaceuticals | Lead sponsor of trials | 2004 to now |